Ahmed M. Elamir

Assistant professor (tenure track) 

East Carolina University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Ahmed M. Elamir is an Assistant Professor (tenure track) at East Carolina University in the United States. His primary research areas focus on the intersection of radiation therapy and immunology, particularly in the context of pancreatic cancer. Dr. Elamir's recent work highlights how presurgical ablative radiation can enhance local control and immune responses in patients with this challenging disease.

Articles (2)

Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P < 0.001), which was significantly reduced with SAbR (HR = 0.28; 95% CI, 0.12–0.68; P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.

Year:

2025

Purpose: To compare outcomes and molecular characteristics of patients who had surgery after neoadjuvant (NA) chemotherapy, with and without stereotactic ablative radiotherapy (SAbR), for pancreatic cancer. Insight could clarify the benefits of SAbR and provide molecular guidance for future therapeutic regimens. Experimental Design: This single-institution, tertiary care academic center cohort study included all patients diagnosed with pancreatic cancer between 2012 and 2023 treated with NA chemotherapy, with or without SAbR. We compared therapeutic responses, performed patient matching, and conducted Cox modeling to identify differences between groups. We assessed molecular response using RNA sequencing to identify SAbR-induced biologic differences. Results: Among 133 patients receiving chemotherapy and 48 receiving chemotherapy + SAbR, RNA sequencing was available for 29 and 14 patients, respectively. Despite more advanced baseline disease, the SAbR group showed better posttreatment pathology and similar overall survival [HR = 0.97, 95% confidence interval (CI), 0.58–1.60, P = 0.9]. Patient matching indicated that SAbR improved locoregional recurrence-free survival (HR = 0.24, 95% CI, 0.07–0.88, P = 0.009). Arterial involvement raised local failure risk with chemotherapy alone (HR = 3.37, 95% CI, 1.74–6.54, P P = 0.005). Gene set enrichment analysis showed immune activation, with CD8 and NK/NKT cell signatures associated with local control and Treg signatures associated with worse control. Conclusions: NA SAbR is associated with improved pathologic outcomes, enhanced local control, and maintained survival while inducing a distinct immune response. Well-powered studies are needed to clarify its clinical benefits.

Year:

2025

Collaborators (12)

Zhikai Chi

University of Texas Southwestern Medical Center

UNITED STATES
View details

Cheryl Lewis

Associate Professor

University of Texas Southwestern

UNITED STATES
View details

Todd Aguilera

University of Texas Southwestern Medical Center

UNITED STATES
View details

John Mansour

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Adam Yopp

Professor of Surgery

University of Texas Southwestern Medical Center

UNITED STATES
View details

Song Zhang

-

UNITED STATES
View details

Matthew R. Porembka

University of Texas Southwestern Medical Center

UNITED STATES
View details

David Hsiehchen

University of Texas Southwestern Medical Center

UNITED STATES
View details

Syed Kazmi

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Patricio M. Polanco

Professor

-

UNITED STATES
View details

Herbert Zeh

Chair of Surgery

University of Texas Southwestern Medical Center

UNITED STATES
View details

Nina N Sanford

University of Texas Southwestern

UNITED STATES
View details